Top news of the week: 01.02.2023.
Active Biotech trial confirms eye treatment safety
Active Biotech has completed phase I clinical study testing the safety and tolerability of its laquinimod eye drop formulation.
Paradox Of China Biotech And What Lies Ahead In 2023
<p>The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take ...
Chowdhury computational research crosses new frontiers in protein structure study
Research led by Department of Chemical and Biological Engineering assistant professor Ratul Chowdhury has landed firmly on the cutting edge of new computational technology in protein ...
AlzeCure Confident Of Bagging Partner For Pain Drug
<p>The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.</p>
Defence's Lung Cancer GLP tox Study on Its Intranasal AccuTOX(TM) Formulation Advances
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology ...
A sharper view inside cells
New methods to improve super-resolution imaging techniques are giving biologists a clearer and more complete view of the inner workings of living cells.
Hit Pause: The Read-Across to Graphite Bio’s CEDAR Sickle Cell Trial Suspension
Why did Graphite Bio stop the trial on its own instead of waiting for the FDA to step in? How are investors and the competition reacting?
AI Has Successfully Imitated Human Evolution—and Might Do It Even Better
The implications are staggering.